State Medicaid Program Issues: Preferred Drug Lists, 2003
This issue brief identifies issues, requirements and considerations relating to preferred drug lists (PDLs). Developed for state audiences, the brief addresses policy, operational and procedural concerns; federal provisions for patient protection; specific case studies; provisions of the Florida Medicaid patient suit settlement agreement; evaluation methodologies; and principles to consider.
E.V.I.dently May 2013
Message From NPCThe Role of Pharmaceuticals in Health Insurance ExchangesOne of the most pressing issues in the implementation of the Affordable Care...
A Look at Rx Coverage and Cost in the New Health Insurance Exchanges
National Pharmaceutical Chief Science Officer Dr. Robert Dubois will lead a panel discussion, "Capturing the Value of Pharmaceuticals--A Look at Rx...Evidence, Coverage and Incentives: Challenges in Personalized Medicine
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...US v. Caronia: Related Resources
The 2nd U.S. Circuit Court of Appeals' recent decision on United States vs. Caronia raises a big question for the pharmaceutical industry: will the...
Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity
(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...NPC Conference to Address Questions on Ability to Share Health Research Findings Health
(Washington, DC, February 6, 2012)--To examine key issues around asymmetries, or inequalities, in communicating health information coming from the...National Pharmaceutical Council Selects Five Research Projects for Funding
Washington, DC (January 30, 2012) – The National Pharmaceutical Council (NPC) today announced that it has selected five projects related to...National Pharmaceutical Council Expands Policy and Research Staff
WASHINGTON, DC (January 4, 2012) -- The National Pharmaceutical Council (NPC) announced the hiring of Daryl Pritchard, PhD, as the Director of...
Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...CER Done Right: Why It Matters
The health care reform law is aimed at reshaping the health care landscape through the creation of many new regulations and regulatory...What Will 2011 Hold for CER and PCORI?
When future historians consider health care, they may well look back on 2010 as a watershed year in America. The issues and events that occurred last...NPC Reflects on Changes in 2010
It’s been a year of great change not only for the biopharmaceutical industry, but for the National Pharmaceutical Council as well. With these changes...
PCORI Outlines Efforts to Engage Patients
Dr. Rachael Fleurence, Scientist,Patient-Centered Outcomes Research Institute, outlines the many ways heragency is engaging patients and other...How Do Payers Consider Individual Treatment Effects?
Dr. Robert Epstein, former chief medical officer and senior vice president of medical affairs at Medco Health, explains that heterogeneity, or...AEI's Gottlieb on Ability to Communicate CER Findings
American Enterprise Institute's Dr. Scott Gottlieb discusses legal and regulatory challenges facing various health care stakeholders in their...UPenn's Dr. Caplan on Communicating CER to Patients
Univ. of Pennsylvania Director of the Center for Bioethics Dr. Art Caplan outlines an ethical framework for communicating comparative effectiveness...A Look at Rx Coverage and Cost in the New Health Insurance Exchanges
National Pharmaceutical Chief Science Officer Dr. Robert Dubois will lead a panel discussion, "Capturing the Value of Pharmaceuticals--A Look at Rx...Evidence, Coverage and Incentives: Challenges in Personalized Medicine
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...US v. Caronia: Related Resources
The 2nd U.S. Circuit Court of Appeals' recent decision on United States vs. Caronia raises a big question for the pharmaceutical industry: will the...US v. Caronia and CER Communications
A landmark appeals court ruling could open the door for the pharmaceutical industry to discuss information about comparative effectiveness research (...Research
Pharmaceutical Benefits Under State Medical Assistance Programs, 2007
This report provides a compilation of data under state medical or state public medical assistance...
Pharmaceutical Benefits Under State Medical Assistance Programs, 2005
This report, part of the Pharmaceutical Benefits Und
Pharmaceutical Benefits Under State Medical Assistance Programs, 2004
This report, part of the Pharmaceutical Benefits Und
- 1 of 40
- >
Commentary & Testimony
Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
CER Done Right: Why It Matters
What Will 2011 Hold for CER and PCORI?
NPC Reflects on Changes in 2010
Time for PCORI’s Implementation